FDA Compounding Facility Types: 503A Compounding Pharmacies: Traditional compounding pharmacies Compound medications based on individual patient prescriptions Regulated primarily by state pharmacy boards Must be licensed in the state where they operate Can ship to patients in states where they hold licenses Subject to state pharmacy board inspections 503B Outsourcing Facilities: Larger-scale compounding operations Registered directly with the FDA Subject to FDA inspections and current good manufacturing practice (cGMP) requirements Can compound without individual patient prescriptions Must report adverse events to the FDA Generally considered to have more stringent oversight FDA Requirements for Legal Compounding: Drug Shortage Requirement: Semaglutide can only be legally compounded while on the FDA drug shortage list Licensed Prescriber: Must be prescribed by a healthcare provider licensed in your state Individual Patient Prescription: 503A pharmacies must have a patient-specific prescription Proper Ingredients: Must use ingredients from FDA-registered suppliers Quality Standards: Must follow United States Pharmacopeia (USP) guidelines State Licensing: Must be licensed by state pharmacy boards USP Chapter 797 Standards: All sterile compounding (including injectable semaglutide) must follow USP Chapter 797, which requires: Cleanroom Environment: ISO Class 5 or better air quality Sterility Testing: Regular testing to ensure no bacterial contamination Personnel Training: Specialized training for compounding staff Quality Control: Documentation and testing of each batch Beyond-Use Dating: Appropriate expiration dates based on stability testing Environmental Monitoring: Regular testing of compounding area What the FDA Does NOT Regulate: The FDA does not approve compounded medications as finished drug products

To all this, we must add that the L-Carnitine used in our formulation is of the best quality and has the Carnipure seal, which means that it is synthesized in the prestigious Swiss laboratory Lonza, guaranteeing the highest purity on the market
In June, a European medical safety committee noted that Wegovy and Ozempic have been linked in very rare cases to the eye condition, Reuters reported, which led Novo Nordisk to update its European labels for Wegovy and Ozempic to state that semaglutide, their active ingredient, may cause NAION in up to 1 in 10,000 patients
Statistical analyses All data analyses and graph generation were performed using GraphPad Prism 10 and presented as mean standard error of the mean (SEM)
RYBELSUS is administered orally as tablets
Choi W, Choe S, Lin J, Borchers MT, Kosmider B, Vassallo R et al (2020) Exendin-4 restores airway mucus homeostasis through the GLP1R-PKA-PPAR-FOXA2-phosphatase signaling